B
BioSpace
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
0:00-19:01
After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.
Publisher
BioSpace
Published
August 12, 2026
Duration
19 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#replimunefinallywins #q2earningswrap #psychedelicsstay #lifesciences
